(-0.07%) 5 474.75 points
(-0.11%) 38 776 points
(-0.02%) 19 917 points
(0.17%) $80.47
(1.26%) $2.82
(0.19%) $2 333.40
(-0.26%) $29.32
(-0.22%) $968.80
(0.00%) $0.932
(-0.20%) $10.63
(0.04%) $0.787
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications...
Stats | |
---|---|
Šios dienos apimtis | 1.22M |
Vidutinė apimtis | 1.29M |
Rinkos kapitalizacija | 941.14M |
EPS | $-0.620 ( Q1 | 2024-05-02 ) |
Kita pelno data | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.70 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0140 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-10 | Rubin Jami | Buy | 42 242 | Common Stock |
2024-06-10 | Rubin Jami | Sell | 42 242 | Stock Option (Right to Buy) |
2024-06-03 | Murcko Mark | Buy | 102 225 | Stock Option (Right to Buy) |
2024-06-03 | Shawver Laura | Buy | 102 225 | Stock Option (Right to Buy) |
2024-06-03 | Rubin Jami | Buy | 102 225 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
85.22 |
Last 99 transactions |
Buy: 4 547 492 | Sell: 387 333 |
Tūris Koreliacija
Relay Therapeutics, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
DCFC | 0.955 |
BGFV | 0.951 |
MAXN | 0.944 |
AMPH | 0.941 |
TXG | 0.939 |
BIVI | 0.937 |
CMTL | 0.937 |
PRTS | 0.935 |
SHC | 0.935 |
NEOG | 0.935 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
SWAV | -0.926 |
IVCB | -0.926 |
WDC | -0.922 |
ESTA | -0.914 |
PNTG | -0.91 |
IMPPP | -0.909 |
GHRS | -0.908 |
RDNT | -0.904 |
ARYD | -0.904 |
BNR | -0.904 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Relay Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos
Relay Therapeutics, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $25.55M |
Bruto pelnas: | $20.28M (79.37 %) |
EPS: | $-2.79 |
FY | 2023 |
Pajamos: | $25.55M |
Bruto pelnas: | $20.28M (79.37 %) |
EPS: | $-2.79 |
FY | 2022 |
Pajamos: | $1.38M |
Bruto pelnas: | $-2.75M (-199.06 %) |
EPS: | $-2.27 |
FY | 2021 |
Pajamos: | $3.03M |
Bruto pelnas: | $3.03M (100.00 %) |
EPS: | $-3.93 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.